Updates on the molecular mechanisms of aspirin in the prevention of colorectal cancer: Review
- 11 January 2021
- journal article
- review article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 27 (4) , 954-961
Abstract
Colorectal cancer is one of the commonest malignancies worldwide. The estimated lifetime risk of the disease is about 5% with an incidence of one million new cases and 600,000 deaths worldwide every year. It is estimated that in 2019, approximately 134,490 new cases of colorectal cancer will be diagnosed with 49,190 mortalities. Though the disease is regarded as a disorder of the more developed world, the occurrence is steadily increasing in many developing countries. Since chronic inflammation is a known aggravating risk factor for colorectal cancer, anti-inflammatory agents such as aspirin have been used to prevent the development of colorectal cancer and related mortality. The potential mechanisms for the effect of aspirin in the prevention of colorectal cancer have been proposed and broadly classified as cyclooxygenase (COX) dependent and COX-independent. Some of the primary effectors of COX-dependent mechanisms in carcinogenesis are likely to be prostaglandins. In contrast to the reversible action of other nonsteroidal anti-inflammatory drugs, aspirin is known to irreversibly inactivate COX enzymes to suppress production of prostaglandins. COX-independent mechanisms of anticancer effects of aspirin include down-regulation of nuclear factor kappa B activity and Akt activation, modulation of Bcl-2 and Bax family proteins, suppression of vascular endothelial growth factor, induction of apoptosis, disruption of DNA repair mechanisms, and induction of spermidine/spermine N1-acetyltransferase that modulates polyamine catabolism.Keywords
This publication has 62 references indexed in Scilit:
- Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer SurvivalNew England Journal of Medicine, 2012
- Aspirin and cancer risk: a quantitative review to 2011Annals of Oncology, 2012
- The role of aspirin in cancer preventionNature Reviews Clinical Oncology, 2012
- Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes MetastasisCancer Cell, 2011
- Aspirin for the prevention of colorectal cancerBest Practice & Research Clinical Gastroenterology, 2011
- Non-Steroidal Anti-Inflammatory Drugs and Colorectal Cancer Risk in a Large, Prospective CohortAmerican Journal of Gastroenterology, 2011
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in MenGastroenterology, 2008
- Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2New England Journal of Medicine, 2007
- Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal CancerJAMA, 2005